BISC 2024 | Professor Yunsong Yu: The Current Epidemic Situation and Challenges of CRO Infections in China

BISC 2024 | Professor Yunsong Yu: The Current Epidemic Situation and Challenges of CRO Infections in China

In recent years, the detection rate of carbapenem-resistant Gram-negative bacteria (CRO) in China has remained high, posing serious challenges to clinical treatments and patient outcomes. The limited therapeutic options have left many clinical needs unmet. At the recent Fourth National Conference on Bacterial and Fungal Infections organized by the Chinese Medical Association (BISC 2024), Professor Yunsong Yu from Zhejiang Provincial People's Hospital delivered a presentation titled "The Current Epidemic Situation and Challenges of Carbapenem-Resistant Organisms (CRO) Infections in China." Professor Yu detailed the prevalence and treatment status of CRO in China and explored the clinical challenges and strategies in depth.
Professor Rong Fan: Precision Screening for Liver Cancer Patients in China

Professor Rong Fan: Precision Screening for Liver Cancer Patients in China

Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of cancer death in China, posing a serious threat to the health and well-being of the population. Reducing the burden associated with liver cancer remains a major challenge in the fields of public health and chronic disease prevention in China. Optimizing screening strategies for liver cancer populations is an important ongoing focus and direction. On April 15, 2024, the National Health Commission released the "Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 Edition)," recommending the aMAP, aMAP-2, and aMAP-2 Plus series of liver cancer risk scoring developed by the research team of Professor Jinlin Hou/Professor Rong Fan from Southern Medical University's Southern Hospital for screening and monitoring high-risk liver cancer populations. At the recent 2024 Greater Bay Area Hepatology Summit and the Conference on the Elimination of Viral Hepatitis, Professor Rong Fan delivered an outstanding report titled "Precision Screening for Liver Cancer Patients in China." Our publication has specially invited Professor Rong Fan to provide an in-depth discussion on this hot topic of concern.
Professor Chunrong Ju Provides a Comprehensive Overview of IFD Diagnosis and Treatment Strategies in SOT Recipients at BISC 2024

Professor Chunrong Ju Provides a Comprehensive Overview of IFD Diagnosis and Treatment Strategies in SOT Recipients at BISC 2024

Solid Organ Transplantation (SOT) is a crucial procedure for saving the lives of patients with end-stage organ failure. In recent years, the field of SOT has flourished in China, with significant improvements in the number of transplants and treatment outcomes. However, infections remain a critical factor affecting the survival and quality of life of SOT recipients. Among these, the incidence and mortality rates of invasive fungal diseases (IFD) are particularly high, especially among lung transplant recipients. At the recent 4th National Conference on Bacterial and Fungal Infections organized by the Chinese Medical Association (BISC 2024), the journal "Infection Medicine Today" had the opportunity to interview Professor Chunrong Ju from The First Affiliated Hospital of Guangzhou Medical University. Professor Ju shared her expert insights on the prevalence, current treatment landscape, and diagnostic challenges of IFD in SOT recipients, as well as discussed strategies for improving treatment outcomes through precision medicine.
Professor Yujie Wu: Standardized Flow Cytometry Detection of CLL-MRD | The 15th Experimental Diagnostic Hematology Conference of the Chinese Medical Association and the 1st Conference on Rare Blood Diseases

Professor Yujie Wu: Standardized Flow Cytometry Detection of CLL-MRD | The 15th Experimental Diagnostic Hematology Conference of the Chinese Medical Association and the 1st Conference on Rare Blood Diseases

As spring blossoms and nature revives, the 15th Experimental Diagnostic Hematology Conference and the 1st Conference on Rare Blood Diseases, hosted by the Chinese Medical Association, were grandly held in the city of Gusu on March 23-24, 2024. The conference invited renowned experts and scholars from the field of hematology both domestically and internationally to deliver enlightening academic presentations and engage in thematic discussions. The aim was to foster academic exchange and cooperation in the fields of experimental diagnostic hematology and rare blood diseases, to share the latest research findings, discuss industry trends, and collectively promote the prosperity of hematology in China. At the conference, Professor Yujie Wu from Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University) delivered an excellent presentation titled "Standardized Flow Cytometry Detection of CLL-MRD," which is specially compiled here for our readers' enjoyment.

Dr. Jimmy Che-To LAI, two award winners, talks about the 2024 APASLAnnual Meeting

From March 27 to 31, 2024, the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2024) was held in Kyoto, Japan. As a top international conference, this year's APASL annual meeting brings together a large number of the latest research progress. After the feast, the heat did not abate. In the multi-day academic feast, what important research, cutting-edge views have been released, and what novel news events have occurred, let us listen to Dr. Jimmy Che-To LAI of the Chinese University of Hong Kong, China, and once again feel the pulse of Asia in the field of liver disease.

Dialogue Interview丨Dr. Jacob George & Dr. Xiaolong Qi discuss frontier hotspots of Metabolic Associated Fatty Liver Disease

The 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL 2024) was held in Kyoto, Japan from March 27 to 31, 2024. Metabolic-associated fatty liver disease (MAFLD) was one of the hot topics in the congress. MAFLD has become a common chronic liver disease worldwide and is caused by metabolic dysfunction. MAFLD is the main reason for the surge in the incidence of liver cirrhosis, liver failure, and liver cancer. In recent years, the incidence of MAFLD has been rising due to changes in lifestyles with high calorie, energy-dense diets and lack of exercise. During the conference, Dr. Jacob George from Westmead Hospital, University of Sydney, Australia, and Dr. Xiaolong Qi, founder of CHESS and Zhongda Hospital, School of Medicine, Southeast University, China, had in-depth exchanges and discussions on the prevalence trends, diagnosis and treatment progress, and comprehensive management of MAFLD. Hepatology Digest hereby reports.
Professor Shunqing Wang: Optimizing SAA Hematopoietic Stem Cell Transplantation to Improve Survival and Quality of Life for More Patients | The 19th National Conference on Red Blood Cell Disorders (Anemia) by the Chinese Medical Association

Professor Shunqing Wang: Optimizing SAA Hematopoietic Stem Cell Transplantation to Improve Survival and Quality of Life for More Patients | The 19th National Conference on Red Blood Cell Disorders (Anemia) by the Chinese Medical Association

Severe aplastic anemia (SAA) has a sudden onset, severe symptoms, and progresses rapidly. With deepening understanding and continuous breakthroughs in research, hematopoietic stem cell transplantation (HSCT) has been applied in this field, significantly improving clinical efficacy and prognosis for patients. At the recent 19th National Conference on Red Blood Cell Disorders (Anemia) held in China, Professor Shunqing Wang from The First People's Hospital of Guangzhou shared insights into the diagnosis and treatment challenges of SAA, advancements in hematopoietic stem cell transplantation therapy, and highlights from the conference.
Professor Liang Wang:Advances in Ocular Lymphoma Research | Inaugural Academic Forum of the Ocular Lymphoma Collaborative Group

Professor Liang Wang:Advances in Ocular Lymphoma Research | Inaugural Academic Forum of the Ocular Lymphoma Collaborative Group

Ocular lymphoma is the most common malignant tumor within the orbit in adults, and its pathological diagnosis and classification are complex, often leading to missed and misdiagnosed cases. Improving the diagnosis rate of ocular lymphoma to better protect patients' ocular and overall health is a significant challenge for ophthalmologists. On March 30, 2024, the inaugural academic forum of the Ocular Lymphoma Collaborative Group was successfully held in Beijing, hosted by the Beijing Tongren Hospital affiliated with Capital Medical University, the Chinese Association for the Promotion of Human Health Science and Technology, the Beijing Public Health Science Popularization Association, and the Beijing Chen Jumei Charity Foundation, and organized by the Cell Immunotherapy Committee of the Chinese Association for the Promotion of Human Health Science and Technology. Renowned experts and scholars from home and abroad actively exchanged and vigorously discussed the latest advances and hot issues in the diagnosis and treatment of ocular lymphoma. Professor Liang Wang, the group leader of the collaborative group from Beijing Tongren Hospital and chairman of the conference, was specially invited by the journal "Oncology Frontier - Hematology Frontier" for an interview to share the latest research developments and achievements in ocular lymphoma.
Professor Hongyan Tong:Progress in Myelodysplastic Syndromes Research, Current Challenges, and Treatment Strategies | Seventh Beijing Thrombosis and Hemostasis Conference and Fifth Beijing Hematology Oncology and Immunology Summit Forum

Professor Hongyan Tong:Progress in Myelodysplastic Syndromes Research, Current Challenges, and Treatment Strategies | Seventh Beijing Thrombosis and Hemostasis Conference and Fifth Beijing Hematology Oncology and Immunology Summit Forum

From March 2nd to 3rd, 2024, the "Seventh Beijing Thrombosis and Hemostasis Conference and the Fifth Beijing Hematology Oncology and Immunology Summit Forum" was successfully held in Beijing. The event was organized by the National Clinical Research Center for Hematologic Diseases - Peking University Institute of Hematology and the Chinese Academy of Medical Sciences Peking Union Medical College Hospital. Numerous domestic and international hematological experts shared the latest advancements in the treatment of coagulopathy and malignant hematologic diseases through keynote reports, paper exchanges, case displays, and panel discussions. During the conference, Oncology Frontier - Hematology Frontier had the privilege of interviewing Professor Hongyan Tong from the Hematology Department of the First Affiliated Hospital of Zhejiang University School of Medicine. Professor Tong discussed the latest research developments, current challenges, and treatment strategies for Myelodysplastic Syndromes (MDS), which we summarize as follows.
EBMT China’s Voice | Professor Ruijuan Sun’s Team:Enhancing Pre-Treatment Protocols in allo-HSCT to Effectively Reduce Relapse Rates in High-Risk AML

EBMT China’s Voice | Professor Ruijuan Sun’s Team:Enhancing Pre-Treatment Protocols in allo-HSCT to Effectively Reduce Relapse Rates in High-Risk AML

Editor’s Note: Since 2008, the World Health Organization (WHO) has recognized t(6;9)(p22;q34)/DEK-NUP214 fusion gene-positive acute myeloid leukemia (AML) as a distinct subtype. This type of AML is characterized by a low incidence rate, high malignancy, a high risk of relapse after chemotherapy, and very poor prognosis. Hematopoietic stem cell transplantation can significantly improve these poor outcomes, although the relapse rate after transplantation remains high. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) annual meeting took place in Glasgow, UK. At this conference, a study by Dr. He Hai from the team of Professor Ruijuan Sun at Hebei Yanda Lu Daopei Hospital in China was presented as a poster. The study revealed that strengthening the pre-treatment regimen in allo-HSCT for treating AML patients with t(6;9)/DEK-NUP214 could effectively reduce the post-transplant relapse rate. This journal has specially invited Dr. He Hai to share the research findings and their clinical significance with peers immediately.